Browse > Article
http://dx.doi.org/10.4070/kcj.2011.41.7.379

Parameters to Guide Retreatment After Initial Intravenous Immunoglobulin Therapy in Kawasaki Disease  

Kim, Hyun-Kwon (Department of Pediatrics, Ewha Womans University School of Medicine)
Oh, Jung-Eun (Department of Pediatrics, Ewha Womans University School of Medicine)
Hong, Young-Mi (Department of Pediatrics, Ewha Womans University School of Medicine)
Sohn, Se-Jung (Department of Pediatrics, Ewha Womans University School of Medicine)
Publication Information
Korean Circulation Journal / v.41, no.7, 2011 , pp. 379-384 More about this Journal
Abstract
Background and Objectives: We sought to determine parameters to guide the decision of retreatment in patients with Kawasaki disease (KD) who remained febrile after initial intravenous immunoglobulin (IVIG). Subjects and Methods: A total of 129 children with KD were studied prospectively. Patients were treated with IVIG 2 to 9 days after the onset of disease. Laboratory measures, such as white blood cell (WBC), percentage of neutrophils, C-reactive protein (CRP), and N-terminal pro-brain natriuretic peptide (NT-proBNP), were determined before and 48 to 72 hours after IVIG treatment. Patients were classified into IVIG-responsive and IVIG-resistant groups, based on the response to IVIG. Results: Of a total of 129 patients, 107 patients (83%) completely responded to a single IVIG therapy and only 22 patients (17%) required retreatment: 14 had persistent fever and 8 had recrudescent fever. There was no significant difference between the groups in age, gender distribution, and duration of fever to IVIG initiation, but coronary artery lesions developed significantly more often in the resistant group than in the responsive group (31.8% vs. 2.8%, p=0.000). Compared with pre-IVIG data, post-IVIG levels of WBC, percentage of neutrophils, CRP, and NT-proBNP decreased to within the normal range in the responsive group, whereas they remained high in the resistant group. Multivariate logistic regression indicated that neutrophil counts, CRP, and NT-proBNP were independent parameters of retreatment. Conclusion: Additional therapy at an early stage of the disease should be administered for febrile patients who have high values of CRP, NT-proBNP, and/or neutrophil counts after IVIG therapy.
Keywords
Kawasaki disease; Intravenous immunoglobulins; Retreatment;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
Times Cited By SCOPUS : 0
연도 인용수 순위
1 Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341-7.   DOI   ScienceOn
2 Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144-8.   DOI   ScienceOn
3 Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:E78.   DOI   ScienceOn
4 Reller M, DeCristofaro J, Schwartz DC. Coronary aneurysms in a patient with atypical Kawasaki syndrome and a streptococcal infection. Pediatr Cardiol 1984;5:205-7.   DOI   ScienceOn
5 Johnson D, Azimi P. Kawasaki disease associated with Klebsiella pneumoniae bacteremia and parainfluenza type 3 virus infection. Pediatr Infect Dis 1985;4:100.
6 Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123:657-9.   DOI   ScienceOn
7 Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80.   DOI   ScienceOn
8 Research committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo: Ministry of Health and Welfare;1984.
9 Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137:177-80.   DOI   ScienceOn
10 Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6.   DOI   ScienceOn
11 Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12.   DOI   ScienceOn
12 Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7.   DOI   ScienceOn
13 Song MS, Lee SB, Sohn S, et al. Infliximab treatment for refractory Kawasaki disease in Korean children. Korean Circ J 2010;40:334-8.   DOI   ScienceOn
14 Muta H, Ishii M, Egami K, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004;144:496-9.   DOI   ScienceOn
15 Tse SM, Silverman ED, McCrindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr 2002;140:450-5.   DOI   ScienceOn
16 Suzuki H, Noda E, Miyawaki M, Tacheuchi T, Uemura S, Koike M. Serum levels of neutrophil activation cytokines in Kawasaki disease. Pediatr Int 2001;43:115-9.   DOI   ScienceOn
17 Samada K, Igarashi H, Shiraishi H, Hatake K, Momoi MY. Increased serum granulocyte colony-stimulating factor correlates with coronary artery dilatation in Kawasaki disease. Eur J Pediatr 2002;161:538-41.   DOI   ScienceOn
18 Hamamichi Y, Ichida F, Yu X, et al. Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: its possible role in progression of coronary artery lesions. Pediatr Res 2001;49:74-80.   DOI   ScienceOn
19 Takahashi K, Oharaseki T, Naoe S, Wakayama M, Yokouchi Y. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 2005;47:305-10.   DOI   ScienceOn
20 Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71.   DOI   ScienceOn
21 Lee H, Kim H, Kim HS, Sohn S. NT-pro BNP: a new diagnostic screening tool for Kawasaki disease. Korean J Pediatr 2006;49:539-44.   DOI
22 Dahdah N, Siles A, Fournier A, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 2009;30:810-7.   DOI   ScienceOn